We Understand the Value of Strong Collaborations

For the U.S. and EU markets, we are seeking a pharmaceutical industry partner for Imeglimin for the Phase 3 clinical development program and commercialization. In Japan, we have the opportunity to advance Imeglimin through a Phase 3 program and will seek a commercial partner for this market. We collaborate on an ongoing basis with academic leaders in metabolic disease, cardiovascular disease and mitochondrial dysfunction.

We have entered into a licensing agreement with Enyo Pharma based in Lyon, France, granting Enyo access to our FXR (farnesoid X receptor) agonist. Enyo has advanced this program into a Phase 1 study for Hepatitis B.

Our Academic Collaborators

  • CarMeN Laboratoire de recherche Cardiovasculaire, Métabolisme, Diabétologie et Nutrition, Université Lyon
  • INSERM U1055, Grenoble, France
  • INSERM U1060, Université Lyon, INRA U 1235
  • INSA Lyon, Hospices Civils
  • University Hospital of Ulm, Faculty of Medicine, Ulm, Germany
  • Faculté de Médecine Pierre et Marie Curie, Paris, France
  • Pauls Stradins Clinical University Hospital, Riga, Latvia
  • Yale University, New Haven, CT, USA

Our Industry Collaborators

  • Merck Serono
  • Enyo Pharma

Interested in Collaborating with Us?

We'd love to hear from you and discuss partnership opportunities.

Contact Us